Advances in immune checkpoint inhibitors for hepatocellular carcinoma
- Author:
Ji Won HAN
1
;
Su-Hyung PARK
Author Information
- Publication Type:Review Article
- From:Journal of Liver Cancer 2021;21(2):139-145
- CountryRepublic of Korea
- Language:English
- Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immune checkpoint blockades do not derive clinical benefit. Thus, there remains an urgent need for novel immunotherapeutic strategies with improved therapeutic efficacy. Here we review recent studies of immune checkpoint blockade in HCC, providing the necessary basis for the rational design of immunotherapy.
